CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies

Frontiers in Immunology

Immunology

Iris Lodewijk¹  Jesus M. Paramio¹  Marta Dueñas¹  Carolina Rubio¹ 

[1] Biomedical Research Institute I+12, University Hospital “12 de Octubre”, Madrid, Spain;Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain;Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain;

关键词: CD44v6;    STn;    O-GD2;    Cancer;    Targeted Therapy;    O-glycans;    Tn;    GD2;   

DOI  :  10.3389/fimmu.2023.1272681

 received in 2023-08-04, accepted in 2023-09-14,  发布年份 2023

来源: Frontiers

【 摘 要 】

Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tumors or the generation of good binders to these antigens, represent a major bottleneck. Specialized cellular mechanisms, such as differential splicing and glycosylation processes, are a good source of neo-antigen expression. Changes in these processes generate surface proteins that, instead of showing decreased or increased antigen expression driven by enhanced mRNA processing, are aberrant in nature and therefore more specific targets to elicit a precise anti-tumor therapy. Here, we present promising TAAs demonstrated to be potential targets for cancer monitoring, targeted therapy and the generation of new immunotherapy tools, such as recombinant antibodies and chimeric antigen receptor (CAR) T cell (CAR-T) or Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) for specific tumor killing, in a wide variety of tumor types. Specifically, this review is a detailed update on TAAs CD44v6, STn and O-GD2, describing their origin as well as their current and potential use as disease biomarker and therapeutic target in a diversity of tumor types.

【 授权许可】

Unknown   
Copyright © 2023 Lodewijk, Dueñas, Paramio and Rubio